In addition to treating co-morbidities, specific medications have been shown to have specific benefits for those with DM and CKD, including glucagon-like peptide-1 receptor agonists (GLP-1 RAs), antiplatelet medications, and non-steroidal mineralocorticoid receptor antagonists (Ns-MRA). This evidence concerns the gene GLP1R and chronic kidney disease.